^
    1m
    A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) (clinicaltrials.gov)
    P2, N=200, Recruiting, Amgen | Trial completion date: Sep 2029 --> Nov 2030 | Trial primary completion date: Sep 2027 --> Nov 2028
    Trial completion date • Trial primary completion date
    |
    AMG 193
    3ms
    A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) (clinicaltrials.gov)
    P1, N=350, Recruiting, Amgen | N=188 --> 350
    Enrollment change
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • AMG 193 • daraxonrasib (RMC-6236)
    4ms
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, Amgen | Trial completion date: Aug 2025 --> Jan 2026 | Trial primary completion date: Aug 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397 • AMG 193
    7ms
    A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) (clinicaltrials.gov)
    P1/2, N=649, Recruiting, Amgen | Trial completion date: Jun 2028 --> Nov 2028 | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
    |
    docetaxel • AMG 193
    8ms
    A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Homozygous MTAP-Deletion Advanced Thoracic Tumors (Master Protocol) (ChiCTR2500095932)
    P=N/A, N=312, Not yet recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New trial
    |
    PD-L1 (Programmed death ligand 1) • MTAP (Methylthioadenosine Phosphorylase)
    |
    PD-L1 expression • MTAP deletion
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • AMG 193
    8ms
    Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers. (PubMed, J Med Chem)
    Preclinical data indicate that AMG 193 is brain-penetrant. AMG 193 is currently in Phase I/II clinical trials for the treatment of advanced MTAP-deleted solid tumors.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    AMG 193
    9ms
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=184 --> 53 | Trial completion date: Feb 2027 --> Aug 2025
    Enrollment closed • Enrollment change • Trial completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397 • AMG 193
    10ms
    A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors (clinicaltrials.gov)
    P1/2, N=649, Recruiting, Amgen | Trial completion date: Jan 2028 --> Jun 2028
    Trial completion date
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
    |
    docetaxel • AMG 193
    10ms
    A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (clinicaltrials.gov)
    P2, N=200, Recruiting, Amgen | Trial completion date: Feb 2029 --> Sep 2029 | Trial primary completion date: Feb 2027 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    AMG 193
    10ms
    A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors (clinicaltrials.gov)
    P1/2, N=649, Recruiting, Amgen | Trial completion date: Oct 2027 --> Jan 2028 | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
    |
    docetaxel • AMG 193
    11ms
    A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (clinicaltrials.gov)
    P2, N=200, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AMG 193
    11ms
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=184, Recruiting, Amgen | Trial completion date: Sep 2027 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397 • AMG 193